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Abstract
Background and objective: The dose-response relationship of inhaled corticosteroid (ICS)/fast-onset long acting
beta agonist (LABA) reliever therapy has not been formally addressed. The objective of this retrospective analysis
is to ascertain from the available evidence whether ICS/fast-onset LABA administered as reliever therapy has a
different dose-response relationship than maintenance fixed dose ICS/fast-onset LABA therapy in reducing risk of
severe exacerbations.
Methods: A systematic literature review was undertaken to identify randomised controlled trials (RCTs) in which
randomised treatments included either i) budesonide/formoterol reliever monotherapy versus budesonide/
formoterol fixed dose maintenance with short acting beta agonist (SABA) reliever therapy, or ii) budesonide/
formoterol reliever therapy in addition to budesonide/formoterol maintenance versus higher fixed dose
maintenance budesonide/formoterol with SABA as reliever therapy. Eligible studies were reviewed to allow
determination of the relative potency and efficacy of the comparator regimens to reduce the risk of a severe
exacerbation.
Results: The one RCT of budesonide/formoterol reliever monotherapy showed a 4.6-fold (95% CI 2.9 to 7.3) greater
potency than budesonide/formoterol fixed dose maintenance plus SABA reliever therapy in reducing the risk of
severe exacerbations. In the one RCT that compared budesonide/formoterol maintenance and reliever therapy with
higher fixed dose maintenance budesonide/formoterol plus SABA reliever therapy, there was an additional 26%
(95% CI 4 to 42%) reduction in severe exacerbation risk with the addition of budesonide/formoterol reliever therapy
to maintenance budesonide/formoterol, despite a 25% lower total budesonide/formoterol dose.
Conclusion: The limited available evidence suggests that budesonide/formoterol reliever therapy has greater
potency and efficacy than budesonide/formoterol fixed dose maintenance plus SABA reliever therapy in reducing
the risk of a severe exacerbation. This is an important concept which has the potential to guide clinical practice in
asthma, although the small number of studies available highlights the need for further research to better define
these pharmacological properties.
Keywords: Asthma, Dose-response relationships, Inhaled corticosteroids, Long acting beta agonists, Severe
exacerbations
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Background
In adolescent and adult asthma, inhaled corticosteroid
(ICS)/long acting beta agonist (LABA) therapy has
shown efficacy when prescribed according to three regi-
mens: as a fixed maintenance dose ICS/LABA together
with a short-acting beta agonist (SABA) for relief, as an
ICS/fast-onset LABA for both maintenance and reliever
therapy, or as an ICS/fast-onset LABA as sole reliever
therapy [1–6]. Clinicians need to be familiar with the
comparative dose-response relationships of these regi-
mens to enable their optimal implementation in clinical
practice. However, the comparative dose-response rela-
tionships of these ICS/LABA regimens have not been
formally assessed.
The aim of this manuscript is to evaluate evidence
from published randomised controlled trials (RCTs), to
compare the dose-response relationships of combination
ICS/fast-onset LABA when used either as reliever ther-
apy or regular maintenance therapy. The key question
was whether there is evidence that ICS/fast-onset LABA
administered as reliever therapy has a different dose-
response relationship compared to administration as
fixed dose ICS/fast-onset LABA maintenance therapy in
reducing severe exacerbations. An initial systematic re-
view identified that budesonide/formoterol was the only
combination ICS/fast-onset LABA product studied in
RCTs that were potentially eligible for inclusion in the
proposed analysis. As a result, for the purposes of testing
this hypothesis we limited our analysis to data from
RCTs of budesonide/formoterol as the relevant ICS/fast-
onset LABA.
Methods
A systematic search of PubMed, supplemented by a
hand search of respiratory journals, was used to identify
all randomised clinical trials that investigated budeso-
nide/formoterol reliever therapy. We searched for the
following terms: (“single inhaler” or SiT or SMART or
MART or combin* or “maintenance and reliever ther-
apy” or “reliever therapy”) AND (formoterol or eformo-
terol) AND (budesonide).
A total of 546 studies were identified using the above
search terms. Results were filtered to include human
studies written in English language. Additional data was
requested from the corresponding authors of studies
where data for our nominated primary and secondary
outcomes were not reported in the primary paper.
Inclusion and exclusion criteria
Two people examined each paper’s title and abstract,
followed by review of the full paper as necessary. In
order to be included in the analysis, RCTs had to
meet all of the following inclusion criteria:
i. Randomised, controlled clinical trial
ii. Adults and/or adolescents with asthma
iii. Report data on measures of efficacy, including
severe exacerbations
iv. Budesonide/formoterol was administered according
to one of the two following study design categories:
1. To enable assessment of potency, that there were
two randomised arms comprising budesonide/
formoterol reliever monotherapy and budesonide/
formoterol fixed dose maintenance with a SABA as
reliever therapy.
2. To enable assessment of efficacy, that there were
two randomised arms comprising budesonide/
formoterol reliever therapy in addition to
budesonide/formoterol maintenance, and higher
fixed dose maintenance budesonide/formoterol with
a SABA as reliever therapy. For this assessment the
maintenance budesonide dose for the treatment
arm of higher fixed dose maintenance therapy
needed to be at the level that achieves the
maximum achievable benefit, at least 640 μg
budesonide (delivered dose) per day [7].
Studies were excluded if any of the following criteria
were met:
i. Budesonide/formoterol was administered in more
than one device and/or from more than one
inhaler.
ii. Within a randomised treatment group, more than
one dose of budesonide/formoterol was used as
fixed dose maintenance therapy and/or more than
one dose of budesonide/formoterol was used as the
maintenance element of maintenance and reliever
therapy.
Data extraction
Extraction of data was based on reported data summar-
ies. These included counts and proportions of the num-
ber of participants in each treatment arm with a
categorical outcome of interest. For continuous vari-
ables, we extracted means and standard deviations and
the number of participants with these outcomes. The
standard deviations, when not explicitly reported, were
derived from reported standard errors or confidence in-
tervals. The primary efficacy outcome variable for this
analysis was risk of severe exacerbations, defined as the
reported number of participants with at least one
exacerbation, divided by the number of participants ran-
domised to the treatment regimen, and with severe exac-
erbations defined according to the American Thoracic
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Society (ATS)/European Respiratory Society (ERS)
criteria [8]. Secondary outcome variables were a measure
of asthma control (preferably the Asthma Control
Questionnaire (ACQ) score), a measure of lung function
(preferably the forced expiratory volume in one second
(FEV1) and budesonide/formoterol doses.
Data analysis
Two eligible studies were identified: one in the first de-
sign category, for assessment of potency; and one in the
second design category, for assessment of efficacy. As-
sessment of the risk of bias was undertaken according to
standard recommendations [9].
The assessment of potency was evaluated in two
stages. The first stage was to estimate the relative risk of
a severe exacerbation based on the counts of participants
with at least one severe exacerbation in each treatment
arm, together with its confidence interval. The second
stage was to then evaluate the relative potency, in rela-
tion to the mean total cumulative dose of budesonide in
each randomised arm. In the second stage, under the
simplifying assumption that the ratio of mean doses of
budesonide in the budesonide/formoterol combination
therapy in each of the two treatment arms has a one-to-
one relationship with the relative risk of severe exacerba-
tion, dividing the relative risk of exacerbation and its
confidence interval by this ratio should approximate a
confidence interval for potency. This is similar to the
pharmacological principle that relative potency can be
estimated by the ratio of doses required to achieve the
same therapeutic effect [10, 11].
The assessment of efficacy was based on the compari-
son between budesonide/formoterol reliever therapy
combined with budesonide/formoterol maintenance
therapy, versus higher fixed dose budesonide/formoterol
maintenance therapy (at the top of the known dose-
response curve for the ICS component) combined with
SABA as reliever therapy. The difference in efficacy was
expressed as the relative reduction in the risk of severe
exacerbations between the two regimens. This is similar
to the pharmacological principle that relative efficacy
can be estimated from the difference in the maximum
obtainable effect achieved by doses at or beyond the top
of the therapeutic dose response curve [10, 11].
SAS version 9.4 was used.
Results
There was one study [12] identified that met the criteria
for study design 1. Four studies [13–16] were identified
that potentially met the criteria for study design 2
[Fig. 1].
Three of these studies were found to be ineligible
based upon the inclusion and exclusion criteria
described above [14–16]. Thus there was one study that
met the inclusion criteria for study design 2 [13].
There was low risk of bias in these two studies which
were included [Fig. 2].
Study design 1: potency evaluation - budesonide/
formoterol reliever monotherapy versus budesonide/
formoterol fixed dose maintenance therapy
A single study with this design was identified [12]. In
this study, participants with moderate persistent asthma
whose symptoms were either not controlled by low-dose
ICS (≤500 μg beclomethasone per day or equivalent) or
controlled by a fixed combination of low-dose ICS and
LABA twice daily in the 2 months before the study were
randomised to either budesonide/formoterol 160 μg/
4.5 μg (delivered dose; 200 μg/6 μg metered dose), as re-
quired for relief of symptoms, or twice daily budesonide/
formoterol 160 μg/4.5 μg, with terbutaline as required
for relief of symptoms. The proportion of participants
with at least one severe exacerbation during the study
was 31/424 (7.3%) in the budesonide/formoterol reliever
monotherapy group and 31/442 (7.0%) in the budeso-
nide/formoterol maintenance group [Table 1].
The estimated relative risk (95% CI); reliever versus
maintenance was 1.04 (0.65 to 1.68), P = 0.87. The re-
ported mean cumulative dose of budesonide/formo-
terol was 24.5/0.69 mg in the reliever group and
116.8/3.2 mg in the maintenance group. Dividing the
point estimate and confidence interval for the relative
risk by this ratio of ICS/LABA doses gives an ap-
proximate point estimate and confidence interval for
potency for reliever compared to maintenance ICS of
4.6 (2.9 to 7.3) This is consistent with budesonide/
formoterol being approximately three to seven times
more potent in reducing the risk of severe exacerba-
tions, when used as reliever monotherapy compared
with regular maintenance use.
In contrast, the secondary clinical outcomes of ACQ
score and FEV1 were significantly improved with main-
tenance budesonide/formoterol therapy. As a result rela-
tive potencies for these clinical outcome measures could
not be calculated.
Study design 2: efficacy evaluation-budesonide/
formoterol maintenance and reliever therapy versus
higher fixed dose budesonide/formoterol maintenance
therapy
One study with this design was included [13]. In this
study, participants with asthma and bronchodilator
reversibility with FEV1 ≥ 50% predicated who had been
using ICS for ≥3 months and who had ≥1 exacerba-
tion in the last 1–12 months were randomised to one
of three arms: budesonide/formoterol 160/4.5 μg (de-
livered dose; 200/6 μg metered dose) one inhalation
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twice daily maintenance therapy plus budesonide/for-
moterol 160/4.5 μg as required for relief of symptoms;
budesonide/formoterol 320/9 μg (delivered dose; 400/
12 μg metered dose) one inhalation twice daily main-
tenance therapy with terbutaline as required for relief
of symptoms; or fluticasone/salmeterol 125/25 μg
(metered dose) two inhalations twice daily mainten-
ance therapy (equivalent to 640 μg budesonide and
18 μg formoterol per day delivered dose), plus terbu-
taline as required for relief of symptoms.
The budesonide/formoterol maintenance and re-
liever group had a decreased risk of severe exacerba-
tions compared with the higher fixed dose
budesonide/formoterol group, with the proportion of
participants with at least one severe exacerbation 94/
1107 (8.5%) and 126/1105 (11.4%) respectively, a
relative risk (95% CI) of 0.74 (0.58 to 0.96), P = 0.02
[Table 2].
The calculated dose ratio for ICS/LABA administra-
tion was 0.75; derived from the mean daily dose of bude-
sonide/formoterol of 483/13.6 μg for budesonide/
formoterol maintenance (320/9 μg) and reliever (163/
4.6 μg) therapy, and 640/18μg for the higher mainten-
ance budesonide/formoterol regimen. As a result, when
added to budesonide/formoterol 320/9 μg/day mainten-
ance therapy, budesonide/formoterol 163/4.6 μg/day as
reliever therapy had greater efficacy than an additional
budesonide/formoterol 320/9 μg/day as maintenance
therapy.
In contrast, the ACQ and FEV1 were similar between
the two regimens, suggesting similar efficacy for these
clinical outcomes.
Fig. 1 The process of inclusion of studies in the systematic review. Abbreviations: BUD: Budesonide. FORM: Formoterol
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Schematic dose response curves
The schematic dose-response curves of severe exacerba-
tion risk for budesonide/formoterol reliever therapy and
maintenance budesonide/formoterol therapy regimens
are shown in Fig. 3.
Discussion
In this retrospective analysis, we have identified from
the limited available evidence that budesonide/formo-
terol reliever therapy has greater potency and efficacy
than budesonide/formoterol fixed dose maintenance
plus SABA reliever therapy in reducing the risk of severe
exacerbations. The difference for potency was substantial
with an estimated 4.6 (2.9 to 7.3) fold difference with
budesonide/formoterol reliever monotherapy compared
with budesonide/formoterol fixed maintenance therapy.
There was an additional 26% (4 to 42%) reduction in se-
vere exacerbation risk with budesonide/formoterol re-
liever therapy when added to maintenance budesonide/
formoterol compared with higher fixed dose mainten-
ance budesonide/formoterol therapy and SABA reliever
therapy, despite a 25% reduction in total budesonide/for-
moterol dose. For the secondary clinical outcomes, there
were no substantial differences in efficacy between the
two regimens, and although it was not possible to calcu-
late differences in potency, fixed dose maintenance ther-
apy was associated with a statistically but not clinically
significant improvement in FEV1 and ACQ score com-
pared to budesonide/formoterol reliever therapy.
There are a number of methodological issues crucial
to the interpretation of these findings. Firstly, despite the
extensive literature search, the only RCTs eligible for in-
clusion used budesonide/formoterol as the ICS/fast-on-
set LABA. Consequently, the generalisability of the
findings of this study beyond budesonide/formoterol to
other ICS/formoterol products is limited to some extent.
There were only two RCTs eligible for inclusion in this
study which reduced the confidence in the estimates of
the differences observed, however, they were large, well
powered RCTs with low risk of bias [12, 13].
Secondly, there is a therapeutic contribution of ICS
and LABA components of both the reliever and main-
tenance therapy regimens. Therefore, the finding of
increased potency and efficacy of budesonide/formoterol
when used as a reliever compared to a maintenance
regimen must be viewed in the context of this combin-
ation. Previously, budesonide in combination with
formoterol as reliever therapy has been shown to reduce
risk of severe exacerbations by 33% when compared with
formoterol reliever therapy alone [17]. Furthermore, the
addition of formoterol to budesonide as fixed
Fig. 2 Assessment of bias
Table 1 Study Design 1. Budesonide/formoterol reliever therapy vs budesonide/formoterol fixed dose maintenance therapy
Papi et al.12 Reliever Therapy Maintenance Therapy Relative Risk (95% CI) P
Risk of severe exacerbations:
(No. participants with at least one severe exacerbation/
No. participants randomised to treatment regimen)
31/424 (7.3%) 31/442 (7.0%) 1.04 (0.65 to 1.68) 0.87
Ratio
Cumulative dose:
Budesonide (mg) 24.5 116.8 0.21
Formoterol (mg) 0.69 3.2 0.22
Potency: 4.6 (2.9 to 7.3)
Difference (95% CI)
FEV1 (L, change from baseline, mean (SD)) −0.16 (0.37) −0.01 (0.34) 0.15 (0.09 to 0.20) < 0.0001
ACQ score (mean change from baseline) 0.25 (0.92) 0.06 (0.74) −0.21 (− 0.34 to − 0.08) < 0.002
Abbreviations: FEV1: Forced expiratory volume in one second; ACQ: Asthma Control Questionnaire
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maintenance therapy has been associated with a 17% re-
duction in severe exacerbation risk [18].
When comparing the efficacy of budesonide/formo-
terol maintenance and reliever therapy and higher fixed
dose budesonide/formoterol maintenance and SABA re-
liever therapy, the effect of the additional SABA reliever
use cannot be separated from the overall efficacy of this
latter regimen. If SABA reliever therapy has a beneficial
clinical effect, then use of SABA will lead to an under-
estimate of the benefit of the budesonide/formoterol
reliever therapy over budesonide/formoterol mainten-
ance therapy.
Airway inflammation is variable in patients with
asthma, suggesting the dose of anti-inflammatory treat-
ment may need to vary in response. At times of rela-
tively increased airway inflammation, a fixed dose ICS/
LABA maintenance regime may provide an insufficient
ICS dose and at times of relatively decreased airway in-
flammation, a fixed dose regime may provide an exces-
sive ICS dose. The titration of ICS dose to severity of
Table 2 Study Design 2 - Budesonide/formoterol maintenance and reliever therapy vs higher fixed dose budesonide/formoterol
maintenance therapy




Relative Risk (95% CI) P
Risk of severe exacerbations:
(No. participants with at least one severe exacerbation/
No. participants randomised to treatment regimen)
94/1107 (8.5%) 126/1105 (11.4%) 0.74 (0.58 to 0.96) 0.02
Mean dose: Ratio
Budesonide (μg/day) 483 (320 maintenance; 163 reliever) 640 0.75
Formoterol (μg/day) 13.6 (9 maintenance; 4.6 reliever) 18 0.75
Difference (95% CI)
FEV1 (L, mean (SD)) 2.69 2.66 0.01 (−0.03 to 0.04) –
Asthma symptoms score (mean total score) 1.06 1.07 0.00 (−0.07 to 0.06) –
Abbreviations: FEV1: Forced expiratory volume in one second
Fig. 3 Schematic dose-response curves of severe exacerbation risk for the budesonide/formoterol reliever therapy (orange/green) and the
maintenance budesonide/formoterol therapy (blue) regimens based on data presented in this review. The X-axis represents the daily dose of
budesonide/formoterol on a logarithmic scale. The Y-axis represents the response in terms of reduction in risk of a severe exacerbation. There
were a number of assumptions made in deriving this figure: i) the budesonide/formoterol reliever therapy curve is derived from the study of
budesonide/formoterol reliever monotherapy [12] (orange) and the study of budesonide/formoterol reliever therapy used in addition to
maintenance budesonide/formoterol therapy [13] (green). ii) the therapeutic effect of budesonide/formoterol reliever monotherapy is set as 50%
of the maximum drug response and the therapeutic effect of budesonide/formoterol maintenance and reliever therapy is set as 100% of the
maximum drug response. iii) the shape of the log exponential dose-response curve is assumed
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airway inflammation which can be achieved by an ICS/
fast-onset LABA reliever regime, has the potential to re-
duce these periods or relative over and under treatment,
which is reflected by the greater potency and efficacy
respectively.
Severe exacerbations as defined by the ATS/ERS were
the primary outcome variable used to assess potency
and efficacy in this paper [8]. This is because severe ex-
acerbations are generally regarded as a crucial asthma
clinical outcome due to the resulting resource use and
the strong association with an increased risk of mortality
[19]. For secondary clinical outcome variables, measures
of asthma control and lung function were utilised. For
both potency and efficacy, there was a major difference
between the regimens in terms of risk of severe exacer-
bations, whereas for asthma control and lung function,
there was no major difference in efficacy. Differences in
potency could not be assessed, however maintenance
therapy was associated with a small but statistically sig-
nificant improvement in FEV1 and ACQ score compared
to budesonide/formoterol reliever therapy, both of which
were below the minimal clinically important difference
of 0.23 L [20] and 0.5 [21] respectively.
The estimates of ICS dose taken during the RCTs were
calculated either from the dose counter on each inhaler,
or self-completed diaries, which may be subject to inac-
curacies of self-report. Perhaps of greater importance is
the potential for enhanced treatment adherence to main-
tenance therapy in the context of a clinical trial, which
would be expected to lead to an under-estimate of the
comparative real world effect of budesonide/formoterol
reliever therapy.
For the calculation of efficacy of the higher fixed dose
maintenance budesonide/formoterol maintenance regi-
men, the budesonide dose was at the top of the dose-
response curve [7]. This suggests that it was reasonable
to use this randomised treatment as a comparator to as-
sess the maximum obtainable benefit of the higher fixed
dose maintenance budesonide/formoterol regimen.
A further study worthy of consideration was not eli-
gible for inclusion in this review because it investigated
ICS/SABA reliever monotherapy [22]. Combination
beclomethasone diproprionate (BDP)/albuterol 250 μg/
100 μg as required for relief of symptoms, was compared
with twice daily BDP/albuterol 250 μg/100 μg with albu-
terol 100 μg as required for relief of symptoms [22]. The
composite outcome of severe exacerbations comprising
three variables, including the need for treatment with
oral steroids, was reported. The number of severe exac-
erbations in the BDP/albuterol reliever and BDP/albute-
rol maintenance groups were 0/122 (0%) and 3/109
(2.8%) respectively. The zero cell count means that rela-
tive risk cannot be calculated, however the absolute risk
difference (95% CI) was 2.8% (− 0.3 to 5.8%), P = 0.10
(Fishers exact test). The cumulative mean dose of BDP
was 18.5 mg and 77.1 mg in the reliever and mainten-
ance groups respectively, a dose ratio of 0.24. It there-
fore seems likely, even though a relative risk cannot be
estimated, that the ICS/SABA reliever monotherapy
regimen is considerably more potent than the mainten-
ance ICS/SABA regimen. This is consistent with the po-
tency estimates for ICS/LABA reliever monotherapy
reported in our analysis.
Conclusions
The limited evidence available indicates that budeso-
nide/formoterol reliever therapy has greater potency and
efficacy than regular maintenance budesonide/formo-
terol plus SABA reliever therapy in reducing the risk of
severe exacerbations. Specifically, the results from our
analysis indicate budesonide/formoterol reliever therapy
can achieve the same effect as maintenance budesonide/
formoterol at about one fifth of the dose, and achieve a
greater maximum effect when added to maintenance
budesonide/formoterol therapy compared with a higher
maintenance fixed dose of budesonide/formoterol. Al-
though based on a small number of studies, we consider
this is an important concept which requires further in-
vestigation. We propose that knowledge of this differ-
ence in the dose-response relationship between fixed
dose ICS/fast-onset LABA maintenance therapy and
ICS/fast-onset LABA reliever therapy has the potential
to guide evidence-based clinical practice.
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